Diabetes Metab J.  2015 Apr;39(2):173-174. 10.4093/dmj.2015.39.2.173.

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)

• Sicras-Mainar A
• Navarro-Artieda R

• KMID: 1805902
• DOI: http://doi.org/10.4093/dmj.2015.39.2.173

Abstract

No abstract available.

MeSH Terms

Humans
Metformin*
Metformin

Reference

1. Sicras-Mainar A, Navarro-Artieda R. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients. Diabetes Metab J. 2015; 39:74–81.

2. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2013; 28:262–274.

3. Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014; 5:138–146.

4. Liu Y, Hu Y. Novel DPP-4 inhibitors against diabetes. Future Med Chem. 2014; 6:793–808.

5. Davidson MH. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014; 126:56–65.